# Free Market Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/free-market-health

- Industry: Healthcare IT
- Headquarters: Pittsburgh, US
- Website: www.freemarkethealth.com
- Total disclosed funding: $34M
- Latest round: Series B (Nov 1, 2023)
- Investors on record: 4

## About

Based in Pennsylvania, US, and founded in 2019 by its CEO Joe Cardosi, Free Market Health Inc. operates as a healthcare technology company that develops a care-driven marketplace platform to empower its stakeholders in optimizing resources. In November 2023, Free Market Health Inc. raised USD 20 million in series B funding led by new investor Questa Capital Management, with participation from returning investors Alta Partners, Highmark Ventures, and 653 Investment Partners.

Free Market Health Inc. offers a cloud-based platform that facilitates specialty medication referral and pharmacy. It orchestrates Highmark’s program configuration, ensuring referrals are assigned to participating specialty pharmacies to maintain continuity of care, based on specific patient care needs and health plan program design. Free Market Health Inc. program provides a prior-authorization submission process and helps identify value drivers and accountabilities for drug authorizations and referrals for patients.

The company plans to use the November 2023 funding to expand its marketplace platform, initiate channel collaboration options, and carry out major commercial expansion.

## Funding rounds

- Series B, Nov 1, 2023, $20M — Alta Partners, Questa Capital, Highmark Ventures, 653 Investment Partners
- Series A, Apr 19, 2022, $14M — Alta Partners, Highmark Ventures, 653 Investment Partners

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A, Series B
- Highmark Ventures (https://capitalatlas.ai/funds/highmark-ventures) — Series A, Series B
- 653 Investment Partners (https://capitalatlas.ai/funds/653-investment-partners) — Series A, Series B
- Questa Capital (https://capitalatlas.ai/funds/questa-capital) — Series B